Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.52 |
| ▸ | KDR | P35968 | 4/20 | 0.51 |
| ▸ | KIT | P10721 | 1/20 | 0.48 |
| ▸ | RAF1 | P04049 | 1/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.46 |
| ▸ | FLT1 | P17948 | 1/20 | 0.46 |
| ▸ | FLT4 | P35916 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29238336 | 0.93 | EGFR (0.44) | EGFRKDRKITRAF1FLT4 | |
| SCHEMBL29238245 | 0.93 | EGFR (0.44) | EGFRKDRKITRAF1FLT4 | |
| SCHEMBL29238223 | 0.93 | PDGFRB (0.44) | EGFRKDRKITRAF1FLT4 | |
| SCHEMBL26535477 | 0.92 | EGFR (0.43) | EGFRKDRKITRAF1FLT4 | |
| SCHEMBL26100122 | 0.92 | RAF1 (0.47) | EGFRKDRKITRAF1FGFR1 | |
| SCHEMBL26101800 | 0.89 | EGFR (0.52) | EGFRKDRKITSRC | |
| SCHEMBL29238266 | 0.89 | PDGFRB (0.41) | EGFRKDRFLT4 | |
| SCHEMBL31137774 | 0.87 | EGFR (0.54) | EGFRKDRRAF1 | |
| SCHEMBL26100102 | 0.83 | EGFR (0.62) | EGFRKDRKIT | |
| SCHEMBL26101259 | 0.82 | EGFR (0.44) | EGFRKDRKITFLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138959-A1 | QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF | VORONOI INC (KR) | 2026-05-21 | — | — | US | claimed |
| EP-4424675-A1 | QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF | Voronoi Inc. (KR) | 2024-09-04 | — | — | EP | claimed |
| CN-118201909-A | Quinazoline derivative compound and use thereof | 株式会社沃若诺伊 | 2024-06-14 | — | — | CN | claimed |
| US-20260138959-A1 | QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF | VORONOI INC (KR) | 2026-05-21 | — | — | US | disclosed |
| EP-4424675-A1 | QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF | Voronoi Inc. (KR) | 2024-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260138959-A1 | QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF | PDGFRA, KIT, PDGFRB | EGFR 79/4885KDR 5/4885KIT 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.